JW Holdings
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
JW Holdings is a holding company, a firm that owns and oversees a group of subsidiaries, whose underlying businesses produce pharmaceutical ingredients, finished medicines, and medical devices.
It sits at the top of that corporate structure, earning income through subsidiary dividends, brand-licensing fees, administrative services provided to affiliates, and by handling overseas business for the raw materials and finished products its subsidiaries make. Listed on KOSPI, Korea's main stock exchange, it also directly manages international sales activities on behalf of its subsidiary and grandchild companies.
Summary is AI-generated and may contain errors · figures from DART filings
JW Holdings was spun off from JW Jungwoe Pharmaceutical as a separate holding company and later renamed JW Holdings, a structure common among larger Korean corporate groups.
JW Holdings in five facts
What does JW Holdings do?
JW Holdings is a holding company, a firm that owns and oversees a group of subsidiaries, whose underlying businesses produce pharmaceutical ingredients, finished medicines, and medical devices.
Where is JW Holdings listed and in which sector?
JW Holdings (Korean name: JW홀딩스) trades under KRX code 096760 on KOSPI, the main board of the Korea Exchange. It is classified in the Financials sector, Diversified Financials.
How large is JW Holdings?
Its market capitalisation was US$224.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were JW Holdings's latest annual revenue and operating profit?
For fiscal year 2025, JW Holdings reported revenue of US$731.8M, operating profit of US$126.7M and net income of US$87.2M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 9.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Change in shares held by the largest shareholderOct 7
- Report on large shareholdings (5% rule) (standard)Oct 7
- DisclosureSep 29
- Operating results (preliminary) (fair disclosure)
JW Holdings filed provisional (unaudited) separate results for Q2 2026: revenue of US$22.5M (+67.6% year on year), operating profit of US$10.9M (+350.7% year on year) and net income of US$5.52M (from a loss a year earlier).
Earnings · Aug 11 - Operating results (preliminary) (fair disclosure)
JW Holdings filed provisional (unaudited) separate results for Q1 2026: revenue of US$13.7M (−25.53% year on year), operating profit of US$4.84M (−44.45% year on year) and net income of US$3.89M (−52.23% year on year).
Earnings · May 12 - [Amended] Supply contract signed (voluntary)
JW Holdings updated a previously disclosed supply contract with GLAND PHARMA LIMITED, now worth US$19M, about 4.17% of its recent annual revenue.
Supply contract · Mar 26 - Decision to acquire shares/equity in another company
JW Holdings disclosed an acquisition of Solidus Investment Co., Ltd., worth US$20.8M.
M&A · Mar 13 - [Amended] Cash/in-kind dividend decision (subsidiary)Dividend · Mar 11 · 3 versions
- [Amended] Cash/in-kind dividend decision
JW Holdings updated its declared cash dividend of US$0.15 per share, equal to about 5.6% of the recent share price.
Dividend · Mar 11 · 2 versions - [Amended] Cash/in-kind dividend decision (subsidiary)Dividend · Mar 11 · 2 versions
- Change of less than 30% in revenue or profit/loss structure (voluntary)
JW Holdings reported consolidated results for FY2025: revenue of US$664M (+9.16% year on year), operating profit of US$115M (+14.87% year on year) and net income of US$81.5M (−3.14% year on year).
Earnings · Feb 5 - Change of 30% or more in revenue or profit/loss structure (15% for large companies) (subsidiary)Earnings · Feb 2